Kangtai Bio’s third-quarter revenue misses Goldman Sachs expectations, while lower impairments lift net profit above forecasts
A declining birth rate and industry competition weighed on revenue. Overseas business grew rapidly but remained a small share of the total. Goldman Sachs cut its revenue forecasts for the next three years, raised its net profit forecasts and maintained a Neutral rating.
Goldman Sachs ·